Article Text

Download PDFPDF

  1. D. Martínez-López1,
  2. D. Prieto-Peña2,
  3. C. Corrales-Selaya2,
  4. P. Szczęsny3,4,
  5. A. Notarnicola5,6,7,
  6. R. Blanco2,
  7. I. E. Lundberg5,6,7,
  8. M. Dastmalchi5,6,7
  1. 1Hospital de Sierrallana, Rheumatology, Torrelavega, Spain
  2. 2Hospital Universitario Marqués de Valdecilla, Rheumatology, Santander, Spain
  3. 3National Institute of Geriatrics, Rheumatology and Rehabilitation, Rheumatology, Warsaw, Poland
  4. 4Medical University of Warsaw, Neurology, Warsaw, Poland
  5. 5Department of Medicine, Karolinska Institutet, Rheumatology, Stockholm, Sweden
  6. 6Karolinska University Hospital, Department of Gastro, Dermatology and Rheumatology, Stockholm, Sweden
  7. 7Karolinska Institutet, Center for Molecular Medicine, Stockholm, Sweden


Background Statin-induced immune mediated necrotizing myopathy (IMNM) is a subtype of inflammatory myopathy associated with anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) autoantibodies. This condition is characterized by progressive muscle weakness leading to severe disability. Treatment is not well established, but usually includes high doses of glucocorticoids (GCs). Therapeutic effects are often disappointing. Side effects are common and related to the high doses of GCs. Intravenous immunoglobulins (IVIG) may be effective in the treatment of IMNM.

Objectives To compare two therapeutic protocols in IMNM; a) standard therapy including high doses of GCs, and b) a GC-free protocol.

Methods Patients consecutively diagnosed with statin-induced IMNM in our centers from January 2017 to November 2022 and followed for at least 3 months were included.

IMNM was diagnosed according to the definition of the European Neuromuscular International Workshop 2016 [1].

Clinical data was extracted retrospectively from the patients’ clinical records.

Remission was defined as no disease activity according to 2016 ACR/EULAR response criteria in myositis [2,3].

Treatment was assigned to the patients considering the current recommendations and contraindications of the therapies available. In patients with comorbidities that limit the use of glucocorticoids, a steroid-free regime was agreed through a shared decision between the physician and the patient.

Results We included 24 anti-HMGCR positive patients. Main features and treatment of the patients are summarized in TABLE 1.

A GC-free regimen based on the use of IVIG 2g/kg every month for at least 3 months was used in 5 (20.8%) patients. The remaining received standard treatment including GCs.

At baseline, general demographic data, MMT-8 and CK levels were similar in both groups. Comorbidities were higher in patients treated with the GCs free protocol.

Remission or low disease activity was achieved in 21 patients (87.5%), including all 5 patients who did not receive GCs (after a mean of 4.1 ± 1.1 months).

However, 3 (15.8%) of the 19 patients receiving glucocorticoids did not achieve remission or low disease activity.

The time to remission or CK normalization was similar in both groups.

Conclusion In our series of patients with anti-HMGCR positive IMNM, we found that patients can achieve remission without glucocorticoid treatment.

References [1]Allenbach Y et al. Neuromuscul Disord. 2018;28(1):87-99

[2]Rider LG et al., Ann Rheum Dis. 2017 May;76(5):782-791. doi: 10.1136/annrheumdis-2017-211401. Erratum in: Ann Rheum Dis. 2018 Apr;77(4):623

[3]Rider LG, et al. Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11(0 11):S118-57.

Table 1.

General features of 24 patients diagnosed with HMGCR positive IMNM.

Acknowledgements: NIL.

Disclosure of Interests David Martínez-López: None declared, Diana Prieto-Peña Grant/research support from: UCB, Roche, Pfizer, Amgen, Janssen, AbbVie/Abbott, Novartis, Eli Lilly, Cristina Corrales-Selaya: None declared, Piotr Szczęsny: None declared, Antonella Notarnicola: None declared, Ricardo Blanco Grant/research support from: RB received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speaker’s bureau from AbbVie, Pfizer, Roche, Bristol-Myers, Lilly, Janssen, and MSD and received support for attending meetings and/or travel from AbbVie, Pfizer, Roche, Bristol-Myers, Lilly, Janssen, and MSD., Ingrid E. Lundberg Grant/research support from: Argenx, AstraZeneca, Bristol Myers Squibb, Novartis, Corbus, EMD Serono, Roche, Pfizer, Orphazyme, Octapharma, Kezar, Janssen, Maryam Dastmalchi: None declared.

  • Comorbidities
  • Myositis
  • Safety

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.